8-K: OS Therapies Acquires Immuno-Oncology Programs from Ayala Pharmaceuticals, Bolstering Pipeline

OS Therapies has acquired immuno-oncology programs and related intellectual property from Ayala Pharmaceuticals, adding clinical-stage lung and prostate cancer assets to its pipeline and consolidating ownership of its core technology.

Summary

• OS Therapies has acquired all listeria monocytogenes-based immuno-oncology programs and related intellectual property from Ayala Pharmaceuticals.
• The acquisition includes a Phase 2 lung cancer program and a Phase 1 prostate cancer program.
• OS Therapies now has full ownership of the intellectual property related to its lead asset, OST-HER2, for osteosarcoma.
• The deal eliminates a $3.5 million milestone payment to Ayala upon the first BLA filing for OST-HER2.
• It also eliminates $16.5 million in sales milestone payments related to OST-HER2.
• The royalty rate on OST-HER2 sales is reduced from 10% to 1.5% of net sales, payable to the University of Pennsylvania.
• The purchase price is $8 million, consisting of $0.5 million in cash and $7.5 million in OS Therapies common stock.
• OS Therapies anticipates submitting a BLA for OST-HER2 in osteosarcoma in the second quarter of 2025.
• The company hopes to receive BLA approval and a Priority Review Voucher (PRV) by the end of 2025.
• OS Therapies plans to sell the PRV immediately upon issuance.
• The company has completed a $7.1 million financing at $4.00 per share, providing cash runway into 2026.
• The financing agreement prohibits OS Therapies from issuing shares to raise capital for at least 6 months and suspends the issuance of shares under its equity line of credit while the stock price is below $12.00.
• The company's burn rate is approximately $0.4 million per month.

Sentiment

Score: 8

Explanation: The document is positive due to the strategic acquisition, improved financial terms, and extended cash runway. The company is focused on near-term milestones and has a clear path forward. However, there are some risks associated with regulatory approval and the sale of the PRV.

Positives

• The acquisition strengthens OS Therapies' intellectual property portfolio.
• The deal adds clinical-stage assets in lung and prostate cancer to the pipeline.
• Eliminating milestone payments and reducing royalties improves the financial outlook for OST-HER2.
• The company has a cash runway into 2026, reducing near-term financing concerns.
• The appointment of Karim Galzahr to the board brings significant financial and strategic expertise.
• The company is focused on regulatory approval and commercialization of OST-HER2.

Negatives

• The company is issuing $7.5 million in stock as part of the acquisition, which could dilute existing shareholders.
• The transaction is subject to customary closing conditions, which could introduce some uncertainty.
• The company is relying on the sale of a PRV for additional funding, which is not guaranteed.

Risks

• The company's success is dependent on the FDA approval of OST-HER2 and the granting of a Priority Review Voucher.
• There is a risk that the company may not be able to sell the PRV at an acceptable price.
• The company is prohibited from raising capital below $12.00 per share for 6 months, which could limit financial flexibility.
• The company is not planning to initiate new clinical development programs until after FDA interactions around OST-HER2, which could slow pipeline growth.

Future Outlook

OS Therapies anticipates submitting a BLA for OST-HER2 in osteosarcoma in the second quarter of 2025 and hopes to be granted a BLA and related Priority Review Voucher (PRV) from FDA by the end of 2025. The company intends to sell the PRV immediately upon issuance and does not intend to initiate any new clinical development programs until it has completed interactions with FDA around OST-HER2 in osteosarcoma.

Management Comments

• Paul Romness, MHP, Chairman & CEO of OS Therapies, stated that the acquisition completes OS Therapeutics ownership of the key intellectual property underlying our listeria monocytogenes immunotherapy platform.
• Paul Romness also noted that the agreement eliminates certain near-term milestone payment obligations related to OST-HER2 in osteosarcoma, projected sales milestone payments, and significantly reduces our effective royalty rate.
• Karim Galzahr, newly appointed Board Member of OS Therapies, said he is honored to join the board at such a pivotal moment in the Company's journey.
• Galzahr believes the company is positioned to unlock the full potential of its market leading listeria-based immunotherapy platform.

Industry Context

This acquisition aligns with the broader trend of biotech companies consolidating intellectual property and expanding their pipelines through strategic acquisitions. The focus on immuno-oncology and targeted therapies is also consistent with current industry trends. The lung and prostate cancer markets are large and growing, making these assets valuable additions to OS Therapies' portfolio.

Comparison to Industry Standards

• The acquisition of clinical-stage assets is a common strategy in the biotech industry to accelerate pipeline development, similar to acquisitions made by companies like Gilead and AbbVie.
• The elimination of milestone payments and reduction in royalties is a positive financial move, comparable to companies renegotiating licensing agreements to improve profitability.
• The focus on a Priority Review Voucher is a common strategy for companies developing treatments for rare diseases, similar to companies like BioMarin and Ultragenyx.
• The $7.1 million financing is a relatively small raise for a clinical-stage biotech company, but it provides a cash runway into 2026, which is a positive sign for investors.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the strengthened pipeline and improved financial outlook.
• Employees will have new opportunities with the expanded company.
• Patients may benefit from the development of new cancer treatments.
• Creditors will have increased confidence in the company's financial stability.

Next Steps

• OS Therapies will submit a Biologics Licensing Application (BLA) for OST-HER2 in osteosarcoma in the second quarter of 2025.
• The company will seek FDA approval for OST-HER2 and a Priority Review Voucher (PRV) by the end of 2025.
• OS Therapies intends to sell the PRV immediately upon issuance.
• The company will complete the acquisition of the assets from Ayala Pharmaceuticals within 60 days, subject to customary closing conditions.

Key Dates

Keywords

immunotherapy, osteosarcoma, HER2, listeria monocytogenes, lung cancer, prostate cancer, Priority Review Voucher, BLA, acquisition, milestone payments, royalties